Drugs / IMP1734
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06253130 | Dec 2023 → Jun 2027 expected | neoplasm | Eikon Therapeutics | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2026-07-20 | Impact Therapeutics, Inc. | Results ESMO 2026 | 塞纳帕利及PARP1选择性抑制剂（IMP1734、IMP1707）的研究结果入选ESMO impacttherapeutics.com ↗
我们很高兴塞纳帕利及我们的两款新型选择性 PARP1 抑制剂 IMP1734 和 IMP1707 的最新临床数据已被接收在 2026 年 ESMO 年会上进行展示。 |
| 2026-06-01 | Impact Therapeutics, Inc. | Results ASCO 2026 | 英派药业以壁报形式公布 PARP1 选择性抑制剂 IMP1734（EIK1003）单药及联合紫杉醇最新临床数据 impacttherapeutics.com ↗
在49名可评估晚期实体瘤患者中，客观缓解率（ORR）为14.3%，7例均为部分缓解（PR）。 |
| 2025-05-30 | Impact Therapeutics, Inc. | Results 英派药业宣布PARP1选择性抑制剂的数据及临床进展将于2025年ASCO年会上公布 impacttherapeutics.com ↗
PARP1选择性抑制剂IMP1734(EIK1003)首次安全性与疗效数据公布 |
| 2023-09-25 | Impact Therapeutics, Inc. | Regulatory 英派药业宣布PARP1选择性抑制剂（IMP1734）获得美国FDA临床试验许可 impacttherapeutics.com ↗
英派药业宣布，由其自主研究发现，与Eikon Therapeutics合作开发的PARP1选择性抑制剂（IMP1734）已获得美国食品药品监督管理局 (FDA)的临床试验许可，并将于2023年第四季度开展临床I期研究。 |
| 2023-09-11 | Eikon Therapeutics | Regulatory Eikon Therapeutics Announces Business Update Highlighting Pipeline and Clinical Development Progress eikontx.com ↗
Separately, the FDA has cleared IMP1734, a highly selective PARP1 inhibitor developed in partnership with Impact Therapeutics, for Phase 1 study initiation, which will also begin in the fourth quarter. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-07-20 | Impact Therapeutics, Inc. | ESMO 2026 | 塞纳帕利及PARP1选择性抑制剂（IMP1734、IMP1707）的研究结果入选ESMO impacttherapeutics.com ↗ |
| 2026-06-01 | Impact Therapeutics, Inc. | ASCO 2026 | 英派药业以壁报形式公布 PARP1 选择性抑制剂 IMP1734（EIK1003）单药及联合紫杉醇最新临床数据 impacttherapeutics.com ↗ |
| 2025-05-30 | Impact Therapeutics, Inc. | 英派药业宣布PARP1选择性抑制剂的数据及临床进展将于2025年ASCO年会上公布 impacttherapeutics.com ↗ |
| 2023-09-25 | Impact Therapeutics, Inc. | 英派药业宣布PARP1选择性抑制剂（IMP1734）获得美国FDA临床试验许可 impacttherapeutics.com ↗ |
| 2023-09-11 | Eikon Therapeutics | Eikon Therapeutics Announces Business Update Highlighting Pipeline and Clinical Development Progress eikontx.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMP1734 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06253130 ↗ |
| Action | Inhibit | “PARP1 selective inhibitor” NCT06253130 ↗ |
| Route | Oral | “IMP1734 monotherapy; oral tablet(s) daily” NCT06253130 ↗ |
| Target | PARP1 | “PARP1 selective inhibitor” NCT06253130 ↗ |